Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients

Table 2 Patient characteristics and outcome, cohort 2

Patient	Response	Characteristics (m¹/f²; age (y³))	Phototype	Histological type	BRAF Status (wt⁷/mut⁸)	Checkpoint inhibitor therapy	Number of involved organs	Metastasis	Tumor Response at first CT scan¹¹
1	Responders	f, 35	n.a.⁴	SSM⁵	mut	anti-PD1⁹ + anti-CTLA4¹⁰	4	Soft tissue, Lung, Liver, Spleen	PR
2		m, 93	2	SSM	wt	anti-PD1	2	Lymph nodes, Lung	SD^*
3		f, 49	2	SSM	mut	anti-PD1 + anti-CTLA4	4	Lung, Liver, Lymph nodes, Brain	PR
4		f, 43	3	SSM	wt	anti-PD1	4	Lung, Lymph nodes, Soft tissue, Brain	PR
5		f, 54	2	SSM	mut	anti-PD1	2	Soft tissue, Lymph nodes	PR
6		m, 48	n.a.	nodular	wt	anti-PD1	3	Lymph nodes, Soft tissue, Bone	PR
7		m, 57	2	nodular	wt	anti-PD1	7	Soft tissue, Lymph nodes, Kidney, Peritoneum, Lung, Bone, Brain	SD^*
8		f, 53	2	nodular	mut	anti-PD1	1	Lung	SD^*
9		m, 36	2	nodular	wt	anti-PD1	2	Lung, Lymph nodes	PR
10		m, 75	n.a.	nodular	wt	anti-PD1	1	Lung	PR
11		m, 69	2	nodular	wt	anti-PD1	1	Soft tissue	PR
12		f, 49	2	nodular	wt	anti-PD1	1	Lung	PR
13		m, 30	4	nodular	mut	anti-PD1	1	Brain	PR
14		m, 65	2	naevoid	mut	anti-PD1 + anti-CTLA4	4	Soft tissue, Lung, Lymph nodes, Brain	PR
15	Non-Responders	m, 79	2	LMM⁶	wt	anti-PD1	2	Lymph nodes, Liver	SD^*
16		f, 52	2	SSM	mut	anti-CTLA4	5	Soft tissue, Lung, Liver, Mesenterium, Brain	PD
17		m, 68	2	SSM	wt	anti-PD1	8	Soft tissue, Lymph nodes, Lung, Suprarenal gland, Liver, Intestinum, Bone, Brain	PD
18		f, 58	3	nodular	mut	anti-PD1	1	Brain	PD
19		m, 85	3	nodular	wt	anti-PD1	1	Brain	PD
20		m, 60	3	nodular	wt	anti-PD1 + anti-CTLA4	3	Lymph nodes, Lung, Liver	PD
21		m, 75	n.a.	desmoplastic	wt	anti-PD1	2	Lymph nodes, Liver	PD

* pseudoprogression, ¹male, ²female, ³years, ⁴not applicable, ⁵superficial spreading melanoma, ⁶lentigo maligna melanoma, ⁷wild type, ⁸V600E mutation, ⁹anti-programmed-cell-death-protein-1, ¹⁰anti-cytotoxic-T-lymphocyte-associated-protein-4, ¹¹CR Complete Remission, PR Partial Remission, SD Stable Disease, PD Progressive Disease